Drug intelligence / Profile preview

TPH-101

Development stage: Preclinical
Lead developer: Telephus Medical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**TPH-101** is a neutralizing monoclonal antibody developed by Telephus Medical LLC (with engineering support from BioAtla) targeting ENGASE, a key bacterial enzyme involved in infection pathogenesis. It is designed to prevent infections, particularly in high-risk surgical contexts such as septic revision hip and knee arthroplasty, by inhibiting bacterial virulence mechanisms. The program remains in **preclinical development**, focusing on antibody optimization for enhanced efficacy and manufacturability.[7][8]

Other names: Autolysin A monoclonal antibodyAtlA monoclonal antibody

Targets

ENGASE (Endo-beta-N-acetylglucosaminidase)

Beyond the preview

Go deeper on TPH-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPH-101.

Explore the full profile